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A Fresh Look at Huntingtin mRNA
Processing in Huntington’s Disease
Lindsay Romoa,∗, Emily S. Mohnb and Neil Aronina,b,∗
aDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
bRNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA, USA
Abstract. Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by a mutation that expands the
polyglutamine (CAG) repeat in exon 1 of the huntingtin (HTT) gene. Wild-type HTT protein interacts with other proteins to
protect cells against toxic stimuli, mediate vesicle transport and endocytosis, and modulate synaptic activity. Mutant HTT
protein disrupts autophagy, vesicle transport, neurotransmitter signaling, and mitochondrial function. Although many of the
activities of wild-type HTT protein and the toxicities of mutant HTT protein are characterized, less is known about the
activities of HTT mRNA. Most putative HD therapies aim to target mutant HTT mRNA before it is translated into the protein.
Therefore, it is imperative to learn as much as we can about how cells handle both wild-type and mutant HTT mRNA so that
effective therapies can be designed. Here, we review the structure of wild-type and mutant HTT mRNA, with emphasis on
their alternatively polyadenylated or spliced isoforms. We then consider the abundance of HTT mRNA isoforms in HD and
discuss the potential implications of these findings. Evidence in the review should be used to guide future research aimed at
developing mRNA-lowering therapies for HD.
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HTT mRNA IS PROCESSED INTO
SEVERAL ALTERNATIVELY
POLYADENYLATED ISOFORMS THAT
CHANGE THEIR ABUNDANCE IN HD
Experimental Huntington’s disease (HD) therapies
target mutant HTT mRNA before it is processed into
the toxic HTT protein [1–4]. Therefore characteri-
zation of HTT mRNA alternatively polyadenylated
isoforms may inform therapeutic design. Cleavage
and polyadenylation of nascent mRNAs at the end
∗Correspondence to: Lindsay Romo, University of Mas-
sachusetts Medical School, Department of Medicine, 55
Lake Ave. North, Worcester, MA 01655, USA. E-mail:
lindsay.romo@umassmed.edu and Neil Aronin, University of
Massachusetts Medical School, Department of Medicine, 55 Lake
Ave. North, Worcester, MA 01655, USA. Tel.: +1 508 856 3239;
E-mail: neil.aronin@umassmed.edu.
of transcription is a critical step in mRNA maturation
and is directed by nucleic acid motifs in the 3′ untrans-
lated region (UTR) of the transcript [5]. One of the
motifs is a hexanucleotide sequence called a polyA
signal. The canonical polyA signal is AAUAAA,
but other nucleotide variations can elicit cleavage
and polyadenylation at lower efficiency [6–8]. Most
mammalian mRNAs possess multiple cleavage and
polyadenylation sites that give rise to mRNA iso-
forms of varying 3′UTR lengths, a phenomenon
termed alternative polyadenylation [9]. The choice of
cleavage site depends on the transcription rate and the
concentration of RNA binding proteins in the nucleus
[10]. The length of the resulting 3′UTR ultimately
impacts the metabolism of each respective mRNA
isoform (for in-depth review, see reference 11) [11].
Briefly, regulatory factors bind cis elements in the
3′UTR to determine the localization and stability of
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the mature transcript [5, 11–13]. For example, brain-
derived neurotrophic factor (BDNF) is transcribed
into two predominant mRNA 3′UTR isoforms. The
longer isoform is localized to dendrites, where it plays
a role in long-term potentiation [14]. The shorter
isoform stabilizes mRNA in cell bodies after depolar-
ization [14, 15]. The stability of the mature transcript
is dictated by the length of the 3′UTR via interactions
with microRNA (miRNA) and RNA binding proteins
[16, 17]. miRNAs target and destabilize mRNAs, and
most miRNA sites are located in the 3′UTR after
the first polyA site [16]. In T cells, mRNAs with
extended 3′UTRs have twice as many miRNA tar-
get sites and produce less protein than mRNAs with
shorter 3′UTRs [18]. Modulation of mRNA stabil-
ity by RNA binding proteins also leads to changes
in the amount of protein translated [19]. In yeast,
deletions in many RNA binding proteins result in
decreased mRNA steady-state levels [20]. Thus, alter-
native polyadenylation can affect mRNA activity,
stability, and translation [21].
Three HTT mRNA 3′UTR isoforms are produced
via alternative cleavage and polyadenylation at three
different sites (Fig. 1A) [22, 23]. The longest mRNA
isoform is 13.7 kilobases, the mid-length isoform
is 12.5 kilobases, and the shortest isoform is 10.3
kilobases [22, 23]. All three isoforms are conserved
in mice; conservation in other animals is unknown
[23]. The long HTT mRNA isoform polyA sig-
nal, ATTAAA, has higher in vitro cleavage and
polyadenylation rates than the short (AGTAAA) and
mid-length (AAUGAA) isoform signals [6]. How-
ever, the relative abundance of these mRNA isoforms
differs across tissues [22, 23]. For example, the long
isoform is more abundant in the brain while the short
isoform predominates in peripheral tissues such as
liver and muscle [22, 23].
The abundance of HTT mRNA 3′UTR isoforms
changes in HD. Although all three isoforms are found
in HD and control brains, the steady-state abundance
of these mRNA isoforms differs in fibroblasts and
brain tissue of HD patients compared to controls [23].
Isoform changes appear to be tissue-specific and arise
from both HTT alleles [23]. An example of this iso-
form change in the human motor cortex is illustrated
in Fig. 1B. The abundance of the HTT short and
mid-length mRNA isoforms in HD motor cortex is
approximately double that in control, although the
isoforms remain of lower abundance (12% of total
HTT mRNA) than the long isoform. It is possible that
this observed shift in abundance is due to increased
neuronal death in HD, which alters the cell population
in the brain. However, mRNA expression has been
shown to be comparable in HD caudate tissue and
HD caudate neurons, despite extensive neuronal loss
[24]. Moreover, the aforementioned isoform study
used motor cortex from grade 1 and 2 HD brains,
in which neuronal loss is limited [23, 25–27].
The mechanism underlying mRNA 3′UTR isoform
alterations in HD is not established. However, one
study determined that knockdown of an RNA binding
protein, CCR4-NOT transcription complex subunit
6 (CNOT6), in human control fibroblasts resulted
in HTT mRNA 3′UTR isoform amounts similar to
those in HD fibroblasts [23]. Furthermore, CNOT6
expression is decreased in HD patient motor cor-
tex [23]. Taken together, these findings suggest that
altered expression of certain RNA binding proteins
in HD may contribute to mRNA isoform abundance
changes. In addition to CNOT6, three 3′ end pro-
cessing factors are differentially expressed in human
HD motor cortex: CPSF2, PCBP2, and THOC5 [23].
These proteins should also be explored as potential
causes of HTT 3′UTR isoform shifts in HD.
IMPLICATIONS FOR ALTERED
ABUNDANCE OF HTT mRNA 3′UTR
ISOFORMS IN HD
HTT mRNA 3′UTR isoforms are translated into
identical proteins. However, the different HTT 3′UTR
isoforms have distinct localizations, stabilities, polyA
tail lengths, and different sites for RNA binding pro-
teins and microRNAs [23]. In wild-type and HD
fibroblasts, the mid-length mRNA isoform is more
abundant in the cytoplasm whereas the short and long
isoforms are more abundant in the nucleus [23]. The
short isoform has the longest half-life, followed by
the mid-length, then long isoform [23]. This may be
because the polyA tail length of the short isoform is
50 nucleotides longer than that of the mid-length and
long isoforms, both of which have more microRNA
binding sites than the short isoform [23]. Further
work should investigate whether rates of transla-
tion significantly differ among the mRNA isoforms.
Taken together, these findings suggest HTT 3′UTR
shifts in HD impact HTT mRNA and protein load.
The impact of altering mRNA and protein load
due to 3′UTR isoform shifts has been documented in
several other diseases. In patients with non-anterior
uveitis, a single nucleotide polymorphism in the
interferon regulatory factor 5 (IRF5) mRNA creates
a polyadenylation site, resulting in a short mRNA
that is associated with the development of macular
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Fig. 1. HTT mRNA is processed into several alternatively polyadenylated isoforms that change their abundance in HD versus normal human
motor cortex. A) The HTT gene is transcribed into mRNA by RNA polymerase 2 (pol2). During transcription, nascent HTT mRNA can be
alternatively cleaved and polyadenylated at three putative polyA sites in its 3′UTR producing a 10.3 kb (short), 12.5 kb (mid), or 13.7 kb
(long) transcript [22, 23]. These alternatively polyadenylated isoforms are translated into the canonical HTT protein. B) In HD patient motor
cortex, the amount of the short and mid 3′UTR isoforms increases relative to the long isoform [23]. ∗The short 3′UTR isoform forms more
aggregates than the long isoform in vitro [30], suggesting altered isoform abundance may have an impact on the formation of abnormal
protein-protein interactions.
edema [28]. Similarly, single nucleotide polymor-
phisms associated with Parkinson’s disease promote
formation of the longest mRNA isoform of alpha
synuclein [29]. This results in accumulation of the
protein and localization to mitochondria, both in vitro
and in Parkinson’s patient brains, potentially causing
pathology [29]. In HD, the increase in the HTT short
mRNA isoform in patient motor cortex may con-
tribute to toxicity. In vitro experiments have shown
that cells transfected with the more-stable short HTT
mRNA isoform have more aggregates than those
transfected with the long HTT isoform, suggesting
that HTT 3′UTR isoforms differentially affect the for-
mation of abnormal protein-protein interactions [30].
Further studies should investigate whether this affects
HD pathogenesis. Finding one mRNA isoform to be
more pathogenic than the others may provide new
therapeutic strategies for HTT RNA silencing. How-
ever, the exact role of HTT 3′UTR isoform changes
in HD remains to be established.
HTT mRNA IS PROCESSED INTO
SEVERAL SPLICE ISOFORMS THAT MAY
CHANGE THEIR ABUNDANCE IN HD
mRNA splicing occurs concurrently with tran-
scription and polyadenylation. During this process,
splicing proteins interact with cis-factors to exclude
introns and join exons. Like polyadenylation, the
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splicing process is influenced by several factors,
including RNA binding protein concentration,
RNA-RNA base-pairing, and the chromatin envi-
ronment, to produce different transcripts from the
same gene [31]. In fact, alternative splicing and
polyadenylation can be co-regulated by certain
RNA binding proteins [32]. Heterogeneous ribonu-
cleoprotein H (HNRNPH1), a mediator of mRNA
alternative splicing, also suppresses cryptic polyA
sites, and two 3′ end formation proteins—cleavage
and polyadenylation specificity factor (CPSF) and
Symplekin (SYMPK)—also regulate splicing of
internal exons [33, 34]. However, unlike alternative
polyadenylation, alternative splicing results in
mRNA isoforms that are translated into different
protein products, which may have unique functions
or post-translational modifications [31]. For exam-
ple, upon neuronal activation some BDNF splice
variants are localized to dendrites in rat hippocampus
whereas others are restricted to the soma, allowing
for targeted expression of the BDNF protein [35].
HTT nascent mRNA undergoes alternative splic-
ing. The resulting splice isoforms are of low
abundance compared to the most common (canon-
ical) splice isoform, and the translation and function
of most HTT splice variants has not been established
(Fig. 2A) [36]. In wild-type mouse brains, HTT can be
alternatively spliced to lack either exon 28, exon 29
or exons 34–44, or spliced to retain a portion of intron
28; the mRNA isoforms lacking exon 28/29 are also
present in human brains [37, 38]. Isoforms lacking
exon 28/29 or retaining intron 28 are most abundant
in cerebellum and least abundant in the striatum [37].
The mRNA isoform lacking exon 29 is expressed at
lower levels in HD Q150 knock-in mice compared to
wild-type mice (Fig. 2B, ∼20% lower) [37].
Another study identified five more HTT mRNA
splice isoforms in human embryonic stem cell lines
differentiated into neural precursors [39]. The expres-
sion of the mRNA isoforms ranged from 0.8% to
13.6% of the most common transcript. Only one of
these mRNA splice isoforms has also been detected
in human tissues. This isoform is hominid-specific
and contains a previously undiscovered exon between
exons 41 and 42, dubbed 41b [39]. Eighteen addi-
tional alternatively spliced isoforms with abundances
ranging from 1% to 7% of the canonical transcript
have been identified using high-throughput sequenc-
ing of control and HD human brain tissue [36].
However, this study did not attempt to compare
HD to control brains, so it is unclear if the abun-
dance of these HTT splice variants changes in HD
patients. Finally, PCR and sequencing of HTT cDNA
from human brain identified twenty-two mRNA
splice variants, including 41b and a transcript lacking
exons 4–6 [40]. However, the study found no differ-
ence between the abundance of these mRNA splice
isoforms in HD and control human brains [40].
IMPLICATIONS FOR HTT mRNA SPLICE
ISOFORMS IN HD
Many genes alter their splicing in HD patient
brains, potentially due to sequestration of the
splicing factor MBNL1 by mutant HTT mRNA, or
to altered expression of other RNA binding proteins
in HD [41, 42]. The abundance of HTT mRNA
splice isoforms may also change in HD. If the
isoform lacking exon 29 is found to be of lower
abundance in HD patients as it is in HD mice, it may
have functional consequences. Exon 29 contains a
putative binding site for the Tap protein, which is
involved in nuclear export of RNAs [37]. Loss of
this binding site could result in nuclear retention of
the HTT transcripts. However, this mRNA isoform
is of such low abundance in human brain that
it could only be detected after several rounds of
amplification and could not be quantified via PCR
[37]. Another HTT splice variant of interest is the
isoform lacking exons 4–6 identified in human brain.
Exons 4–6 contain a nuclear localization signal, two
post-translational modification sites, and a predicted
binding site for a nuclear localization protein [40].
Thus, a HTT protein lacking these domains may be
localized differently than canonical HTT protein,
which could affect pathology [43]. Evidence for a
role of alternative splicing in disease pathology has
been observed in tauopathies. Alternative splicing of
the microtubule associated protein tau gene results
in six isoforms; shifting the ratio of two of these iso-
forms leads to neurodegeneration in frontotemporal
dementia [44]. For HD, it has not been established
whether HTT mRNA splice isoforms are translated
or whether they impact HD pathology. Future studies
should investigate whether HTT mRNA splice
variants, particularly the isoforms lacking either
exon 28 or exons 4–6, play a role in HD.
AN ABERRANT HTT SPLICE ISOFORM
FOUND IN HD MAY BE PATHOGENIC
Aberrant splicing refers to an abnormal variation in
the splicing process and has been shown to contribute
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Fig. 2. HTT is transcribed into several splice isoforms in normal and HD tissues. A) In normal and HD cells, HTT mRNA can be alternatively
spliced to lack an exon(s), producing a shorter mRNA and protein than the canonical transcript, or to include an extra exon or retain an
intron, producing longer mRNA and protein [36–40]. ∗The translation of these isoforms has yet to be demonstrated. ∗∗However, if translated,
splice variant protein products may have different localization and function. For example, a splice isoform of similar abundance in patient
and control brains that excludes exons 4–6 lacks a nuclear localization signal [40]. B) In wild-type mice, HTT can be alternatively spliced to
lack exon 28, 29, 24–44, or to retain intron 28 [37, 38]. These isoforms are of the same or unknown abundance in HD mouse models except
the variant lacking exon 29, which is of decreased abundance in Q150 HD knock-in mice [37]. ∗∗∗Decreased abundance may have an impact
on HTT localization and function, as exon 29 has a binding site for a protein involved in RNA nuclear export (Tap) [37].
to disease [31]. In spinal motor atrophy, both copies of
the survival motor neuron 1 (SMN1) gene are deleted,
leaving the duplicate SMN2 gene as the only source of
the SMN protein [45, 46]. A frequent nucleotide vari-
ant in the SMN2 gene at a splicing enhancement site
leads to missplicing and an unstable truncated protein
that exacerbates the disease [47]. Aberrant splicing
may also occur in HD. An elegant study published
by the Bates group characterized one truncated HTT
mRNA splice isoform that may be pathogenic [48].
In HD patients and mouse models, but not controls,
HTT is misspliced and polyadenylated at a cryptic
polyadenylation signal in intron 1, producing a trun-
cated transcript [48] (Fig. 3). In mice, production of
the aberrant transcript is correlated with the CAG
repeat number. Although quantitation of this mRNA
isoform is difficult because of its high GC-content and
stable secondary structure, the truncated transcript
has been detected via 3′ RACE (rapid amplification of
cDNA ends) in HD patient, but not control, fibroblasts
and brain tissue [48–50]. This study also observed
higher levels of HTT mRNA containing intron 1 in
patient motor cortex and hippocampus compared to
controls [50].
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Fig. 3. HTT is alternatively spliced into a truncated isoform in HD cells. In HD fibroblasts and brain tissue, the splicing factor SRSF6
processes mutant HTT mRNA into a third alternatively polyadenylated splice isoform that terminates in intron 1. This isoform may be
translated into the pathogenic N-terminal HTT protein prone to aggregation and toxicity [48–50].
Production of the transcript may be controlled by
the serine/arginine-rich splicing factor 6 (SRSF6),
which binds to expanded mutant HTT mRNA with
a higher affinity than to wild-type mRNA (Fig. 3). A
stop codon at the very beginning of intron 1 precludes
the production of an intron-1 specific antibody, but
immunoprecipitation of N-terminal HTT detected a
protein of the appropriate size in HD mouse models
that was not detected in controls [48]. The protein
could not be immunoprecipitated from HD patient
brains, possibly because it is highly prone to aggre-
gation [50]. It has not been established if this protein
represents translation of the truncated splice iso-
form or post-translational cleavage of the full-length
protein. The association of this splice isoform with
disease and the toxicity of N-terminal fragments of
the HTT protein suggest that it could contribute to HD
pathology. If the potential link between this splice iso-
form and disease can be established, intron 1 may be
an exciting new therapeutic target.
CONCLUSIONS
For decades, HD research has focused on the toxic
mutant HTT protein. However, recent studies sug-
gest HTT mRNA may also influence cellular toxicity.
There are multiple alternatively spliced or polyadeny-
lated isoforms of mutant HTT mRNA. The studies
detailed in this review suggest some isoforms of
HTT mRNA may be more toxic than others, either
independently or because of their protein products.
However, research on HTT mRNA structure, activity,
and toxicity is in its infancy with most of the studies
described in this review being correlative. Differen-
tial handling and processing of HTT mRNA may be
a contributor to pathology, or it may be a result of
pathology. Regardless, mutant HTT mRNA is an ideal
target for HD therapeutics because it is translated into
the pathogenic protein, and thus should continue to
be rigorously investigated [4]. This will aid in the
development of more efficient and effective HD ther-
apies designed to target specific mutant HTT mRNA
isoforms. For instance, if the truncated HTT mRNA
isoform is found to be pathogenic, it could be targeted
with interfering RNAs complementary to intron 1. If
the short 3′UTR HTT isoform is found to be toxic,
the proximal polyA site could be disrupted in the
HTT gene. Moreover, knowledge of the differential
pathogenicity and localization of HTT mRNA iso-
forms may suggest cellular compartments that could
be targeted by RNA-lowering therapies. Thus, it is
critical that future research address the current gaps
in knowledge regarding differential toxicity of HTT
mRNA isoforms in an effort to further character-
ize HD pathogenesis and guide recommendations for
HTT mRNA-lowering therapies
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